GlassScriptPhysician profile
David W Sobel
NPI 1881011872
$58,365.51
in general payments reported to CMS, 2019-2025
12 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $4,506 · 2021: $7,754 · 2022: $4,284 · 2023: $15K · 2024: $9,558 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $40K · Travel and Lodging: $1,391 · Food and Beverage: $713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $39,584.54 |
| Travel and Lodging | $1,391.16 |
| Food and Beverage | $713.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $35,058.59 | 2020-2025 | General - Kidney Stone Disease, General - Therapies, Moses 550 D\F\L |
| Gyrus Acmi, INC. | $17,565.65 | 2021-2025 | Soltive |
| Ambu A/S | $2,557.04 | 2024 | |
| Olympus Winter & Ibe Gmbh | $2,313.04 | 2024-2025 | Olympus |
| Axonics, INC. | $234.90 | 2023-2024 | Axonics, Bulkamid |
| Procept Biorobotics Corporation | $155.69 | 2022 | |
| Olympus America INC. | $129.60 | 2024-2025 | Uretero-Reno Videoscope, Uropass, Soltive |
| Astellas Pharma US INC | $99.95 | 2021 | |
| Sumitomo Pharma America, INC. | $71.38 | 2023-2025 | Orgovyx |
| Coloplast Corp | $47.29 | 2019 | |
| Ethicon INC. | $25.21 | 2021 | |
| Abbvie INC. | $21.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sobel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.